Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years

Table 6

Safety parameters of men receiving testosterone treatment (means ± SD).

Visit month

𝑁

Prostate volume (mL)

𝑁

PSA (ng/dL)

𝑁

Residual volume (mL)

𝑁

IPSS score

𝑁

Hemoglobin (g/L)

𝑁

Hematocrit (%)

𝑁

ALT (U/L)

𝑁

AST (U/L)

0 month

45

19.8 ± 7.4

45

0.96 ± 1.05

41

26.0 ± 17.0

45

3.1 ± 3.0

45

14.6 ± 0.6

45

44.4 ± 2.0

45

44.8 ± 21.7

45

43.7 ± 20.9

12 months

16

21.9 ± 9.8

20

1.26 ± 1.00

39

18.7 ± 14.2

43

2.1 ± 2.1

44

14.9 ± 0.5

44

46.4 ± 2.2

44

29.6 ± 14.2

44

27.7 ± 12.6

24 months

10

26.8 ± 10.6

17

1.45 ± 1.05

33

15.5 ± 10.6

35

1.9 ± 1.8

36

15.0 ± 0.4

36

47.7 ± 1.7

36

26.6 ± 11.9

36

26.8 ± 9.6

36 months

12

26.9 ± 9.2

15

1.40 ± 1.12

29

14.7 ± 9.0

32

1.8 ± 1.4

32

15.1 ± 0.4

32

48.4 ± 1.8

32

24.6 ± 8.4

32

25.6 ± 7.9

48 months

8

29.3 ± 10.6

9

1.37 ± 1.19

22

13.0 ± 5.5

25

1.4 ± 0.9

25

15.1 ± 0.4

25

48.4 ± 1.4

25

25.2 ± 5.6

25

25.4 ± 5.9

60 months

3

27.7 ± 16.2

4

1.59 ± 1.20

10

13.5 ± 6.7

10

1.8 ± 1.1

10

15.1 ± 0.4

10

48.0 ± 1.8

10

22.8 ± 5.2

10

22.4 ± 4.8

72 months

3

24.3 ± 16.7

3

1.04 ± 1.21

4

12.5 ± 5.0

4

1.8 ± 1.0

4

15.2 ± 0.3

4

49.0 ± 1.8

4

22.0 ± 3.5

4

21.0 ± 2.9

Difference 60; months-baseline

3.1 ± 0.5^1

0.15 ± 0.09^2

−19.12 ± 2.23^1

−2.5 ± 0.4^1

0.54 ± 0.1^1

3.8 ± 0.4^1

−28.4 ± 2.5^1

−25.5 ± 2.3^1

¹𝑃<0.0001.
2Non significant.
PSA: Prostate specific antigen.
IPSS: International prostate symptom score.
ALT: Alanine aminotransferase.
AST: Aspartate aminotransferase.